Phaseline

Companies › Clover Biopharmaceuticals USA

Clover Biopharmaceuticals USA: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SCB-1019T
Bivalent recombinant RSV vaccine with PreF protein subunits from RSV strains A and B fused
–Phase 1RSV Infection–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06843317SCB-1019TPhase 1RSV InfectionInfectious diseaseMar 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.